HighLight Capital Terms and Conditions
  • Home
  • About
  • Team
  • Portfolio
  • News
  • Contact Us
HighLight Capital Terms and Conditions

Latest News

Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA
2024-02-29

Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA

Tigermed-Jyton’s acquisition of NAMSA China, as well as the exclusive China regional partnership and global collaboration
Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio
2024-02-26

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop
2024-01-02

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Ant
2023-11-06

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Ant

BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTec
2023-10-12

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTec

MediLink announced that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
2023-06-12

Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million

Viva successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.
  • 2
  • 3
  • 4
  • 5
  • 6
  • 31 records in total
HighLight Capital Terms and Conditions
Home
About
Team
Portfolio
News
Contact Us
Copyright © 2014-2025 HighLight Capital Terms and Conditions. All Rights Reserved.